← All drugs
Drug · FAERS side-effect profile with label screen

Prednisolone side effects: what 179,370 FDA adverse event reports show

Prednisolone · 1,306 reaction terms · 670,869 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Corticosteroid

FDA label (Established Pharmacologic Class) · compare the class

Who reports

179,370 reports · 96% serious · 28,710 with death outcome · 53% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Prednisolone Oral Solution USP is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable: in infancy mineralocorticoid supplementation is of particular importance).

FDA label, Indications and Usage

What it is

Prednisolone is a glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group.

PubChem CID 5755 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled (related wording) 8Likely indication confounding 9Lab value / disease marker 5Not in label — unassessed 18
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,266 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Alveolar proteinosis18353.0
44.5–63.1ROR 53.0 · calibrated p 1e-5 ✓
36.4 EB05 32.2 · IC025 +4.8
3/3 methods agree
vs other Corticosteroids: PRR 38.6 (32.3–46.1)
Not in label — unassessedserious n=182 · 100% clinicianno trial arm names this drug
Parvovirus b19 infection27552.9
45.8–61.0ROR 52.9 · calibrated p 1e-5 ✓
36.4 EB05 32.9 · IC025 +4.9
3/3 methods agree
vs other Corticosteroids: PRR 30.7 (26.7–35.3)
Not in label — unassessedserious n=222 · 100% clinicianno trial arm names this drug
C-reactive protein26949.1
42.5–56.6ROR 49.1 · calibrated p 2e-5 ✓
34.6 EB05 31.2 · IC025 +4.8
3/3 methods agree
vs other Corticosteroids: PRR 3.5 (3.1–3.9)
Lab value / disease markerserious n=269 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug
Deep vein thrombosis postoperative54244.5
40.3–49.1ROR 44.6 · calibrated p 3e-5 ✓
32.3 EB05 30.0 · IC025 +4.8
3/3 methods agree
vs other Corticosteroids: PRR 3.2 (2.9–3.5)
Not in label — unassessedserious n=542 · ♀ 100% (drug 53%) · 95% clinicianno trial arm names this drug
Pulmonary nocardiosis22443.9
37.7–51.3ROR 44.0 · calibrated p 3e-5 ✓
31.9 EB05 28.6 · IC025 +4.7
3/3 methods agree
vs other Corticosteroids: PRR 27.6 (23.7–32.1)
Not in label — unassessedserious n=224 · ♀ 33% (drug 53%) · 100% clinicianno trial arm names this drug
Polyomavirus viraemia25740.3
34.9–46.4ROR 40.3 · calibrated p 5e-5 ✓
30.0 EB05 27.0 · IC025 +4.6
3/3 methods agree
vs other Corticosteroids: PRR 28.8 (25.0–33.3)
Not in label — unassessedserious n=256 · 100% clinicianno trial arm names this drug
Strongyloidiasis38936.7
32.8–41.2ROR 36.8 · calibrated p 9e-5 ✓
28.0 EB05 25.8 · IC025 +4.6
3/3 methods agree
vs other Corticosteroids: PRR 12.2 (11.0–13.6)
Not in label — unassessedserious n=387 · ♀ 33% (drug 53%) · 100% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody15334.6
28.9–41.4ROR 34.6 · calibrated p 1e-4 ✓
26.7 EB05 23.3 · IC025 +4.4
3/3 methods agree
vs other Corticosteroids: PRR 2.6 (2.2–3.1)
Lab value / disease markerserious n=153 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug
Polyomavirus-associated nephropathy52634.0
30.9–37.5ROR 34.1 · calibrated p 1e-4 ✓
26.4 EB05 24.6 · IC025 +4.5
3/3 methods agree
vs other Corticosteroids: PRR 16.8 (15.3–18.5)
Likely indication confounding
shares a disease stem with the indications wording
serious n=526 · ♀ 33% (drug 53%) · 100% clinicianno trial arm names this drug
Pneumocystis jiroveci pneumonia51033.9
30.8–37.5ROR 34.0 · calibrated p 1e-4 ✓
26.4 EB05 24.5 · IC025 +4.5
3/3 methods agree
vs other Corticosteroids: PRR 36.0 (32.4–39.9)
Likely indication confounding
shares a disease stem with the indications wording
serious n=507 · 95% clinicianno trial arm names this drug
Mycobacterium chelonae infection16433.3
28.0–39.6ROR 33.3 · calibrated p 2e-4 ✓
26.0 EB05 22.8 · IC025 +4.3
3/3 methods agree
vs other Corticosteroids: PRR 5.4 (4.7–6.4)
Not in label — unassessedserious n=164 · 100% clinicianno trial arm names this drug
Disseminated cryptococcosis14829.3
24.4–35.1ROR 29.3 · calibrated p 3e-4 ✓
23.5 EB05 20.5 · IC025 +4.2
3/3 methods agree
vs other Corticosteroids: PRR 37.8 (31.1–46.0)
Not in label — unassessedserious n=148 · ♀ 0% (drug 53%) · 100% clinicianno trial arm names this drug
Complications of transplanted kidney43528.2
25.4–31.3ROR 28.2 · calibrated p 4e-4 ✓
22.8 EB05 21.0 · IC025 +4.3
3/3 methods agree
vs other Corticosteroids: PRR 18.3 (16.5–20.3)
Not in label — unassessedserious n=432 · ♀ 31% (drug 53%) · 91% clinicianno trial arm names this drug
Cytomegalovirus enterocolitis14828.0
23.4–33.5ROR 28.0 · calibrated p 4e-4 ✓
22.6 EB05 19.7 · IC025 +4.1
3/3 methods agree
vs other Corticosteroids: PRR 38.6 (31.7–47.0)
Not in label — unassessedserious n=148 · ♀ 0% (drug 53%) · 100% clinicianno trial arm names this drug
Diffuse large b-cell lymphoma refractory17827.5
23.4–32.4ROR 27.5 · calibrated p 4e-4 ✓
22.3 EB05 19.7 · IC025 +4.2
3/3 methods agree
vs other Corticosteroids: PRR 22.1 (18.7–26.1)
Likely indication confounding
shares a disease stem with the indications wording
serious n=178 · 100% clinicianno trial arm names this drug
Post transplant lymphoproliferative disorder95727.4
25.5–29.4ROR 27.5 · calibrated p 4e-4 ✓
22.3 EB05 21.1 · IC025 +4.4
3/3 methods agree
vs other Corticosteroids: PRR 16.2 (15.1–17.4)
Likely indication confounding
shares a disease stem with the indications wording
serious n=957 · 100% clinicianno trial arm names this drug
Delayed graft function13427.2
22.5–32.8ROR 27.2 · calibrated p 5e-4 ✓
22.1 EB05 19.1 · IC025 +4.1
3/3 methods agree
vs other Corticosteroids: PRR 22.2 (18.3–26.9)
Not in label — unassessedserious n=134 · ♀ 0% (drug 53%) · 100% clinicianno trial arm names this drug
Epstein-barr virus associated lymphoproliferative disorder33326.9
23.9–30.3ROR 26.9 · calibrated p 5e-4 ✓
21.9 EB05 20.0 · IC025 +4.2
3/3 methods agree
vs other Corticosteroids: PRR 30.6 (27.0–34.7)
Likely indication confounding
shares a disease stem with the indications wording
serious n=332 · 100% clinicianno trial arm names this drug
Cytomegalovirus colitis42226.6
23.9–29.6ROR 26.7 · calibrated p 5e-4 ✓
21.8 EB05 20.1 · IC025 +4.2
3/3 methods agree
vs other Corticosteroids: PRR 18.8 (16.9–20.9)
Likely indication confounding
shares a disease stem with the indications wording
serious n=422 · 94% clinicianno trial arm names this drug
X-ray abnormal32525.9
22.9–29.2ROR 25.9 · calibrated p 6e-4 ✓
21.3 EB05 19.4 · IC025 +4.2
3/3 methods agree
vs other Corticosteroids: PRR 3.1 (2.7–3.4)
Lab value / disease markerserious n=325 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug
Infection in an immunocompromised host13025.7
21.2–31.1ROR 25.7 · calibrated p 7e-4 ✓
21.1 EB05 18.2 · IC025 +4.0
3/3 methods agree
vs other Corticosteroids: PRR 38.6 (31.3–47.6)
Not in label — unassessedserious n=130 · ♀ 0% (drug 53%) · 100% clinicianno trial arm names this drug
Lupus vulgaris21024.9
21.4–28.9ROR 24.9 · calibrated p 7e-4 ✓
20.6 EB05 18.4 · IC025 +4.1
3/3 methods agree
vs other Corticosteroids: PRR 2.1 (1.8–2.4)
Not in label — unassessedserious n=210 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug
Pneumocystis jirovecii pneumonia1,76024.8
23.6–26.1ROR 25.1 · calibrated p 7e-4 ✓
20.6 EB05 19.8 · IC025 +4.3
3/3 methods agree
vs other Corticosteroids: PRR 14.3 (13.6–15.1)
Likely indication confounding
shares a disease stem with the indications wording
age-adj. PRR 19.3 · serious PRR 12.4 · 96% clinicianno trial arm names this drug
Lymphoproliferative disorder51424.6
22.4–27.1ROR 24.7 · calibrated p 7e-4 ✓
20.4 EB05 19.0 · IC025 +4.2
3/3 methods agree
vs other Corticosteroids: PRR 38.6 (34.7–42.9)
Likely indication confounding
shares a disease stem with the indications wording
serious n=512 · 100% clinicianno trial arm names this drug
Chronic allograft nephropathy13323.6
19.6–28.4ROR 23.6 · calibrated p 1e-3 ✓
19.7 EB05 17.0 · IC025 +3.9
3/3 methods agree
vs other Corticosteroids: PRR 38.6 (31.4–47.5)
Likely indication confounding
shares a disease stem with the indications wording
serious n=133 · ♀ 0% (drug 53%) · 100% clinicianno trial arm names this drug
Immunosuppressant drug level decreased19923.3
20.0–27.2ROR 23.3 · calibrated p 0.001 ✓
19.5 EB05 17.3 · IC025 +4.0
3/3 methods agree
vs other Corticosteroids: PRR 38.6 (32.6–45.7)
Lab value / disease markerserious n=196no trial arm names this drug
Swollen joint count increased52023.2
21.1–25.5ROR 23.3 · calibrated p 1e-3 ✓
19.5 EB05 18.1 · IC025 +4.1
3/3 methods agree
vs other Corticosteroids: PRR 2.1 (1.9–2.3)
Lab value / disease markerserious n=520 · ♀ 100% (drug 53%) · 95% clinicianno trial arm names this drug
Cryptococcosis26222.6
19.8–25.8ROR 22.6 · calibrated p 0.001 ✓
19.0 EB05 17.1 · IC025 +4.0
3/3 methods agree
vs other Corticosteroids: PRR 17.1 (15.0–19.6)
Not in label — unassessedserious n=262 · ♀ 0% (drug 53%) · 100% clinicianno trial arm names this drug
Transplant rejection1,30122.5
21.2–23.9ROR 22.7 · calibrated p 0.001 ✓
19.0 EB05 18.1 · IC025 +4.1
3/3 methods agree
vs other Corticosteroids: PRR 17.1 (16.1–18.1)
Not in label — unassessedserious PRR 11.5no trial arm names this drug
Viraemia22222.0
19.1–25.4ROR 22.1 · calibrated p 0.001 ✓
18.6 EB05 16.6 · IC025 +3.9
3/3 methods agree
vs other Corticosteroids: PRR 10.9 (9.5–12.6)
Not in label — unassessedserious n=216 · 100% clinicianno trial arm names this drug
Kidney transplant rejection75421.5
19.9–23.3ROR 21.6 · calibrated p 0.001 ✓
18.3 EB05 17.2 · IC025 +4.1
3/3 methods agree
vs other Corticosteroids: PRR 16.8 (15.5–18.1)
Not in label — unassessedserious n=754no trial arm names this drug
Adjustment disorder with depressed mood31321.3
18.9–24.1ROR 21.4 · calibrated p 0.001 ✓
18.1 EB05 16.5 · IC025 +4.0
3/3 methods agree
vs other Corticosteroids: PRR 2.4 (2.1–2.6)
Not in label — unassessedserious n=313 · ♀ 100% (drug 53%) · 100% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Opportunistic infection7,3886.66.5–6.8signal
Interstitial lung disease4,2555.45.2–5.5signal
Neutropenia / agranulocytosis7,4833.63.5–3.7signal
Osteonecrosis1,7223.63.4–3.7signal
Severe cutaneous reaction1,9863.23.0–3.3signal
Liver injury7,2972.92.8–2.9signal
Serious infection18,5702.92.8–2.9signal
Thrombocytopenia5,1752.82.7–2.9signal
Kidney injury9,5722.52.4–2.5signal
Hyponatraemia1,5992.32.2–2.5signal
Tendon disorder7562.32.2–2.5signal
Anaemia5,7832.32.2–2.3signal
Rhabdomyolysis / myopathy1,4742.12.0–2.3signal
Gi bleeding2,9431.91.8–2.0raised
Pancreatitis1,2901.91.8–2.0raised
Anaphylaxis / angioedema1,7721.71.6–1.7raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Prednisolone only as a background or rescue medication (NCT01471340, NCT01950819); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Off label use (used outside approved label)15,5472.1
2.1–2.1ROR 2.2 · calibrated p 0.942
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
vs other Corticosteroids: PRR 4.6 (4.6–4.7)
Reporting / coding artifactage-adj. PRR 1.9 · serious PRR 2.2 · 90% clinicianno trial arm names this drug
Drug ineffective (drug did not work)12,8061.1
1.1–1.2ROR 1.1 · calibrated p 0.405
1.1 EB05 1.1 · IC025 +0.2
vs other Corticosteroids: PRR 4.2 (4.2–4.3)
Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.8no trial arm names this drug
Pyrexia (fever)8,4612.9
2.8–3.0ROR 3.0 · calibrated p 0.627
2.9 EB05 2.8 · IC025 +1.5
3/3 methods agree
vs other Corticosteroids: PRR 5.8 (5.7–5.9)
Not in label — unassessedage-adj. PRR 2.3 · serious PRR 2.1no trial arm names this drug
Dyspnoea (shortness of breath)7,0711.5
1.4–1.5ROR 1.5 · calibrated p 0.633
1.5 EB05 1.4 · IC025 +0.5
vs other Corticosteroids: PRR 4.2 (4.1–4.3)
Not in label — unassessedage-adj. PRR 1.3 · serious PRR 1.2no trial arm names this drug
Diarrhoea (diarrhea)6,7681.2
1.2–1.3ROR 1.2 · calibrated p 0.468
1.2 EB05 1.2 · IC025 +0.3
vs other Corticosteroids: PRR 4.1 (4.1–4.2)
Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.3no trial arm names this drug
Condition aggravated6,0292.4
2.3–2.4ROR 2.4 · calibrated p 0.853
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
vs other Corticosteroids: PRR 3.8 (3.7–3.9)
Reporting / coding artifactage-adj. PRR 2.1 · serious PRR 2.1no trial arm names this drug
Nausea5,5650.8
0.8–0.8ROR 0.8 · calibrated p 0.194
0.8 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
vs other Corticosteroids: PRR 3.3 (3.3–3.4)
Not in label — unassessedage-adj. PRR 0.7 · serious PRR 0.9no trial arm names this drug
Vomiting5,1581.3
1.3–1.3ROR 1.3 · calibrated p 0.506
1.3 EB05 1.3 · IC025 +0.3
vs other Corticosteroids: PRR 4.1 (4.0–4.3)
Not in label — unassessedage-adj. PRR 1.1 · serious PRR 1.1no trial arm names this drug
Fatigue (tiredness)5,1300.8
0.7–0.8ROR 0.8 · calibrated p 0.164
0.8 EB05 0.8 · IC025 -0.4
PRR-only: not supported by EBGM or IC
vs other Corticosteroids: PRR 2.4 (2.4–2.5)
Not in label — unassessedage-adj. PRR 0.7 · serious PRR 0.8no trial arm names this drug
Product use in unapproved indication5,0252.4
2.4–2.5ROR 2.5 · calibrated p 0.823
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
vs other Corticosteroids: PRR 5.6 (5.4–5.7)
Reporting / coding artifactage-adj. PRR 2.3 · serious PRR 3.1 · 92% clinicianno trial arm names this drug
Headache4,6640.9
0.8–0.9ROR 0.9 · calibrated p 0.222
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
vs other Corticosteroids: PRR 3.2 (3.1–3.3)
Labeled adverse reaction
exact term
age-adj. PRR 0.8 · serious PRR 1.0 · ♀ 74% (drug 53%)no trial arm names this drug
Sepsis (blood infection)4,5765.0
4.8–5.1ROR 5.1 · calibrated p 0.228
4.8 EB05 4.7 · IC025 +2.2
3/3 methods agree
vs other Corticosteroids: PRR 8.6 (8.4–8.9)
Not in label — unassessedage-adj. PRR 3.9 · serious PRR 2.9 · 92% clinicianno trial arm names this drug
Rash4,4091.2
1.2–1.2ROR 1.2 · calibrated p 0.437
1.2 EB05 1.2 · IC025 +0.2
vs other Corticosteroids: PRR 3.0 (2.9–3.0)
Not in label — unassessedage-adj. PRR 1.1 · serious PRR 1.5no trial arm names this drug
Arthralgia (joint pain)4,3131.2
1.2–1.3ROR 1.2 · calibrated p 0.457
1.2 EB05 1.2 · IC025 +0.2
vs other Corticosteroids: PRR 2.9 (2.8–3.0)
Not in label — unassessedage-adj. PRR 1.1 · serious PRR 1.3 · ♀ 76% (drug 53%)no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Corticosteroids (prednisolone) ↔ Avascular necrosis of bone.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Prednisolone?

In FDA FAERS, the most frequently co-reported reaction terms for Prednisolone are pyrexia, dyspnoea, pneumonia, diarrhoea, nausea, vomiting. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Prednisolone have an FDA boxed warning?

No. The FDA label retrieved for Prednisolone has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Prednisolone causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.